Developer docs
API playgroundTry for free, no card

Search company profiles

Deep Genomics

Full company profile

uuid00036xm

Namestring
Deep Genomics
Legal namestring
Deep Genomics Incorporated
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Deep Genomics Incorporated is an AI-driven genetic medicines company founded in 2015 by University of Toronto professor Brendan Frey, headquartered in Toronto with a clinical and business development office in Cambridge, Massachusetts. The company operates the BioFM (Biological Foundation Model) Platform, an integrated discovery engine that combines lab-in-the-loop workflows, proprietary training datasets, AI model development, screening technologies, and software systems. On this common architecture Deep Genomics builds, runs, and improves a stack of proprietary foundation models — most notably BigRNA (nearly 2 billion tunable parameters trained on over one trillion genomic signals, predicting tissue-specific RNA expression, splicing, protein/microRNA binding, and designing steric-blocking oligonucleotides), REPRESS (predicting microRNA binding and mRNA degradation from sequence), and DeepADAR (designing guide RNAs for ADAR-mediated RNA editing). The platform has reported a 70% research-to-therapeutic-lead success rate and target-to-drug-candidate timelines under 12 months, materially shorter than industry-standard drug discovery cycles.

Deep Genomics is organized as an enterprise B2B TechBio that monetizes through strategic partnerships with pharmaceutical and biotechnology companies rather than through direct product sales. Revenue mechanics consist of upfront payments, development and regulatory milestones, and potential royalties on programs the company out-licenses. Named enterprise partners include BioMarin Pharmaceutical (a preclinical collaboration across four rare-disease indications announced in November 2020) and Wave Life Sciences (a neuromuscular splicing collaboration announced in April 2018). The company is advancing 10+ preclinical programs — with the Series C use of funds targeting 30 programs and four clinical entries by 2023 — focused on rare genetic diseases such as Wilson disease and neuromuscular disorders. The internal pipeline runs in parallel with partner-funded programs, allowing Deep Genomics to capture long-tail upside from any programs it advances independently.

Deep Genomics has raised approximately $236.4 million across multiple rounds from SoftBank Vision Fund 2, CPP Investments, Fidelity, Khosla Ventures, True Ventures, Future Ventures, and Amplitude Ventures. Leadership has evolved from a founder-led research organization into a commercially oriented company: founder Brendan Frey moved to Chief Innovation Officer in September 2023 when biotech operator Brian O'Callaghan was appointed CEO, with subsequent additions of a CTO (Radu Dobrin), CSO (Greg Hoffman), VP Machine Learning (Joel Shor), and CBO (Clive Bertram) in 2024. The company has been recognized with the 2024 Stevie Award for BioTechnology Company of the Year and a 2025 Gold Stevie Award for Biotech Executive of the Year (O'Callaghan).

Short descriptiontext

Deep Genomics is an AI-driven genetic medicines company that uses proprietary foundation models (BigRNA, REPRESS, DeepADAR) on its BioFM Platform to discover and design RNA-based therapeutics for rare genetic diseases, partnering with pharmaceutical companies like BioMarin and Wave Life Sciences for development and commercialization.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersToronto, Canada
HQ citystring
Toronto
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, RNA therapeutics, foundation models, genetic medicines, oligonucleotide therapies
Industry4 codes
PRIMARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAE
RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Pharmaceutical Preparations2834
Product category
AI-driven drug discovery platform
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Partnership and Collaboration Revenue
TypeLicensing Royalties
Description

Deep Genomics generates revenue through strategic partnerships with pharmaceutical companies. They receive upfront payments and are eligible for development milestones as programs advance through preclinical and clinical stages. Partners like BioMarin receive exclusive options to obtain rights to programs for development and commercialization.

miragenews.com
2Pipeline Development and Licensing
TypeLicensing Royalties
Description

The company develops proprietary therapeutic candidates through its AI platform and plans to advance programs into the clinic, potentially licensing out or partnering at various stages of development.

deepgenomics.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Deep Genomics operates an AI-driven genetic medicines platform (the BioFM Platform) that uses proprietary biological foundation models—including BigRNA, REPRESS, and DeepADAR—to predict RNA biology mechanisms and design oligonucleotide-based therapeutic candidates for rare genetic diseases. The company partners with pharmaceutical companies like BioMarin and Wave Life Sciences to advance these candidates through clinical development and commercialization in exchange for upfront payments, milestones, and royalties.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 70% of research projects led to therapeutic leads
+3 more records
Product overview1 text field

Deep Genomics operates as an AI-first TechBio organization offering a unified platform called the BioFM (Biological Foundation Model) Platform. The platform comprises multiple AI foundation models including BigRNA (the core RNA biology decoder and therapeutic designer), REPRESS (for microRNA binding and mRNA degradation prediction), and DeepADAR (for ADAR-mediated RNA editing design). These models work in concert within a lab-in-the-loop workflow system, combining computational AI predictions with experimental validation to discover disease mechanisms and design RNA-based therapeutic candidates for genetic diseases.

Product and service4 records
1BioFM Platform
CategoryAI drug discovery platform
Description

Comprehensive AI-driven genetic medicines platform that combines lab-in-the-loop workflows, AI model development, fit-for-purpose training datasets, screening technologies, and software systems to build, run, and improve Biological Foundation Models for drug discovery; used by Deep Genomics internally and made available to pharmaceutical partners to identify disease mechanisms and design RNA-based therapeutic candidates for genetic diseases.

2BigRNA
CategoryAI foundation model
Description

First AI foundation model for RNA therapeutics, with nearly 2 billion tunable parameters trained on over one trillion genomic signals; predicts tissue-specific RNA expression, splicing, microRNA binding, and designs steric blocking oligonucleotides as therapeutic candidates, outperforming state-of-the-art methods in 152 of 153 protein and microRNA binding site predictions.

3REPRESS
CategoryAI foundation model
Description

Deep learning foundation model that predicts cell-type-specific microRNA (miRNA) binding and mRNA degradation directly from RNA sequences, revealing regulatory mechanisms missed by other state-of-the-art methods and outperforming seven leading methods across seven benchmarks; part of the BioFM Platform.

4DeepADAR
CategoryAI foundation model
Description

AI foundation model that designs guide RNAs (gRNAs) to induce ADAR-mediated editing across various trinucleotide contexts, predicting endogenous and gRNA-driven editing based on local sequence and structural features for RNA editing therapeutics.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-09-20
Description

Deep Genomics joined Mila's community to access recruitment activities and collaborate with AI researchers. Partnership supports talent acquisition and long-term AI collaboration with Professor Yoshua Bengio's institute.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-11-17
Description

Preclinical collaboration using Deep Genomics' AI Workbench to identify oligonucleotide drug candidates in four rare disease indications. Deep Genomics receives undisclosed upfront payment and eligible for development milestones. BioMarin receives exclusive option to obtain rights to each program for development and commercialization.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-04-10
Description

Collaboration to discover novel therapies for genetic neuromuscular disorders. Deep Genomics uses machine learning platform to identify cause and effect relationships for splicing regulation targets; Wave uses proprietary chemistry platform to validate targets and elucidate implications across different phenotypes.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI-first drug discovery company combining high-throughput biology with foundation models to identify therapeutic candidates; most directly comparable to Deep Genomics on platform-centric, AI-driven discovery and pharma partnership model.

TypeDirect peer
Description

Machine learning-driven drug discovery platform using large-scale data generation and predictive models; comparable to Deep Genomics in combining proprietary ML with lab experimentation and in targeting genetic and metabolic diseases.

TypeDirect peer
Description

Generative AI platform for designing novel protein therapeutics; closest direct peer on foundation-model architecture for biology and partnership-driven commercialization with pharma.

4Isomorphic Labs
TypeDirect peer
Description

Alphabet-backed AI drug discovery company building foundation models for biology; competes for the same enterprise pharma partnership channel and shared talent pool as Deep Genomics.

TypeDirect peer
Description

AI-driven precision medicine company with partnered and internal pipeline; comparable in business model (pharma partnerships, platform-as-product) and AI-led small-molecule/biologic discovery.

TypeBroad incumbent
Description

Computational chemistry and predictive modeling platform serving pharma R&D; broader portfolio of tools and customers but overlaps significantly with Deep Genomics on AI-enabled molecular design and enterprise pharma go-to-market.

TypeDirect peer
Description

AI- and quantum physics-driven drug discovery platform with partnerships across global pharma; comparable in scale, enterprise sales motion, and platform-as-engine approach to molecular design.

TypeEmerging player
Description

Clinical-stage RNA therapeutics company with proprietary chemistry platform; simultaneously a strategic partner of Deep Genomics and a modality peer — both design nucleic-acid therapeutics for genetic diseases.

TypeEmerging player
Description

RNA-based medicine company using antisense oligonucleotides for genetic diseases; targets similar rare-disease indications as Deep Genomics and competes for partnership and licensing opportunities.

TypeBroad incumbent
Description

Established antisense oligonucleotide therapeutics leader with broad pipeline and partnerships; sets the bar for RNA-targeted genetic medicines and competes with Deep Genomics' oligonucleotide design approach at the modality level.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Deep Genomics

AI-driven drug discovery platformdeepgenomics.com

Deep Genomics is an AI-driven genetic medicines company that uses proprietary foundation models (BigRNA, REPRESS, DeepADAR) on its BioFM Platform to discover and design RNA-based therapeutics for rare genetic diseases, partnering with pharmaceutical companies like BioMarin and Wave Life Sciences for development and commercialization.

What Deep Genomics does

Deep Genomics Incorporated is an AI-driven genetic medicines company founded in 2015 by University of Toronto professor Brendan Frey, headquartered in Toronto with a clinical and business development office in Cambridge, Massachusetts. The company operates the BioFM (Biological Foundation Model) Platform, an integrated discovery engine that combines lab-in-the-loop workflows, proprietary training datasets, AI model development, screening technologies, and software systems. On this common architecture Deep Genomics builds, runs, and improves a stack of proprietary foundation models — most notably BigRNA (nearly 2 billion tunable parameters trained on over one trillion genomic signals, predicting tissue-specific RNA expression, splicing, protein/microRNA binding, and designing steric-blocking oligonucleotides), REPRESS (predicting microRNA binding and mRNA degradation from sequence), and DeepADAR (designing guide RNAs for ADAR-mediated RNA editing). The platform has reported a 70% research-to-therapeutic-lead success rate and target-to-drug-candidate timelines under 12 months, materially shorter than industry-standard drug discovery cycles.

Deep Genomics is organized as an enterprise B2B TechBio that monetizes through strategic partnerships with pharmaceutical and biotechnology companies rather than through direct product sales. Revenue mechanics consist of upfront payments, development and regulatory milestones, and potential royalties on programs the company out-licenses. Named enterprise partners include BioMarin Pharmaceutical (a preclinical collaboration across four rare-disease indications announced in November 2020) and Wave Life Sciences (a neuromuscular splicing collaboration announced in April 2018). The company is advancing 10+ preclinical programs — with the Series C use of funds targeting 30 programs and four clinical entries by 2023 — focused on rare genetic diseases such as Wilson disease and neuromuscular disorders. The internal pipeline runs in parallel with partner-funded programs, allowing Deep Genomics to capture long-tail upside from any programs it advances independently.

Deep Genomics has raised approximately $236.4 million across multiple rounds from SoftBank Vision Fund 2, CPP Investments, Fidelity, Khosla Ventures, True Ventures, Future Ventures, and Amplitude Ventures. Leadership has evolved from a founder-led research organization into a commercially oriented company: founder Brendan Frey moved to Chief Innovation Officer in September 2023 when biotech operator Brian O'Callaghan was appointed CEO, with subsequent additions of a CTO (Radu Dobrin), CSO (Greg Hoffman), VP Machine Learning (Joel Shor), and CBO (Clive Bertram) in 2024. The company has been recognized with the 2024 Stevie Award for BioTechnology Company of the Year and a 2025 Gold Stevie Award for Biotech Executive of the Year (O'Callaghan).

Deep Genomics firmographics

Firmographics
Name
Deep Genomics
Legal name
Deep Genomics Incorporated
Website
https://deepgenomics.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
101–250 employees
Short description
Deep Genomics is an AI-driven genetic medicines company that uses proprietary foundation models (BigRNA, REPRESS, DeepADAR) on its BioFM Platform to discover and design RNA-based therapeutics for rare genetic diseases, partnering with pharmaceutical companies like BioMarin and Wave Life Sciences for development and commercialization.
Ownership category
akta.pro rank

Deep Genomics industry classification

Industry
Product category
AI-driven drug discovery platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAE
RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • AI drug discovery
  • RNA therapeutics
  • Foundation models
  • Genetic medicines
  • Oligonucleotide therapies

Where Deep Genomics is headquartered

Location

Headquarters

HQ city
Toronto
HQ country
Canada
HQ region
North America

Offices2 records

Markets served

Deep Genomics business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Partnership and Collaboration Revenue: Deep Genomics generates revenue through strategic partnerships with pharmaceutical companies. They receive upfront payments and are eligible for development milestones as programs advance through preclinical and clinical stages. Partners like BioMarin receive exclusive options to obtain rights to programs for development and commercialization.
  2. Pipeline Development and Licensing: The company develops proprietary therapeutic candidates through its AI platform and plans to advance programs into the clinic, potentially licensing out or partnering at various stages of development.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Deep Genomics product offering

Product offering

Core offering

Deep Genomics operates an AI-driven genetic medicines platform (the BioFM Platform) that uses proprietary biological foundation models—including BigRNA, REPRESS, and DeepADAR—to predict RNA biology mechanisms and design oligonucleotide-based therapeutic candidates for rare genetic diseases. The company partners with pharmaceutical companies like BioMarin and Wave Life Sciences to advance these candidates through clinical development and commercialization in exchange for upfront payments, milestones, and royalties.

Product overview

Deep Genomics operates as an AI-first TechBio organization offering a unified platform called the BioFM (Biological Foundation Model) Platform. The platform comprises multiple AI foundation models including BigRNA (the core RNA biology decoder and therapeutic designer), REPRESS (for microRNA binding and mRNA degradation prediction), and DeepADAR (for ADAR-mediated RNA editing design). These models work in concert within a lab-in-the-loop workflow system, combining computational AI predictions with experimental validation to discover disease mechanisms and design RNA-based therapeutic candidates for genetic diseases.

Differentiator

Problem solved

Functional benefit

Products and services

  • BioFM Platform Comprehensive AI-driven genetic medicines platform that combines lab-in-the-loop workflows, AI model development, fit-for-purpose training datasets, screening technologies, and software systems to build, run, and improve Biological Foundation Models for drug discovery; used by Deep Genomics internally and made available to pharmaceutical partners to identify disease mechanisms and design RNA-based therapeutic candidates for genetic diseases.
  • BigRNA First AI foundation model for RNA therapeutics, with nearly 2 billion tunable parameters trained on over one trillion genomic signals; predicts tissue-specific RNA expression, splicing, microRNA binding, and designs steric blocking oligonucleotides as therapeutic candidates, outperforming state-of-the-art methods in 152 of 153 protein and microRNA binding site predictions.
  • REPRESS Deep learning foundation model that predicts cell-type-specific microRNA (miRNA) binding and mRNA degradation directly from RNA sequences, revealing regulatory mechanisms missed by other state-of-the-art methods and outperforming seven leading methods across seven benchmarks; part of the BioFM Platform.
  • DeepADAR AI foundation model that designs guide RNAs (gRNAs) to induce ADAR-mediated editing across various trinucleotide contexts, predicting endogenous and gRNA-driven editing based on local sequence and structural features for RNA editing therapeutics.

Quantifiable outcome

  • 70% of research projects led to therapeutic leads
  • +3 more outcomes

Companies that use Deep Genomics

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles1 record

Deep Genomics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability3 records

Feature5 records

Deep Genomics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered minor and core.

  • Mila (Quebec Artificial Intelligence Institute)minorStrategic or Co-development Partner · 20 September 2021Deep Genomics joined Mila's community to access recruitment activities and collaborate with AI researchers. Partnership supports talent acquisition and long-term AI collaboration with Professor Yoshua Bengio's institute.
  • BioMarin Pharmaceutical Inc.coreStrategic or Co-development Partner · 17 November 2020Preclinical collaboration using Deep Genomics' AI Workbench to identify oligonucleotide drug candidates in four rare disease indications. Deep Genomics receives undisclosed upfront payment and eligible for development milestones. BioMarin receives exclusive option to obtain rights to each program for development and commercialization.
  • Wave Life SciencescoreStrategic or Co-development Partner · 10 April 2018Collaboration to discover novel therapies for genetic neuromuscular disorders. Deep Genomics uses machine learning platform to identify cause and effect relationships for splicing regulation targets; Wave uses proprietary chemistry platform to validate targets and elucidate implications across different phenotypes.

Scale indicators3 records

Recent moves7 records

Expansion highlights6 records

Deep Genomics competitors and assessment

Company assessment

Direct peers

  • Recursion Pharmaceuticals: AI-first drug discovery company combining high-throughput biology with foundation models to identify therapeutic candidates; most directly comparable to Deep Genomics on platform-centric, AI-driven discovery and pharma partnership model.
  • Insitro: Machine learning-driven drug discovery platform using large-scale data generation and predictive models; comparable to Deep Genomics in combining proprietary ML with lab experimentation and in targeting genetic and metabolic diseases.
  • Generate:Biomedicines: Generative AI platform for designing novel protein therapeutics; closest direct peer on foundation-model architecture for biology and partnership-driven commercialization with pharma.
  • Isomorphic Labs: Alphabet-backed AI drug discovery company building foundation models for biology; competes for the same enterprise pharma partnership channel and shared talent pool as Deep Genomics.
  • Exscientia: AI-driven precision medicine company with partnered and internal pipeline; comparable in business model (pharma partnerships, platform-as-product) and AI-led small-molecule/biologic discovery.
  • XtalPi: AI- and quantum physics-driven drug discovery platform with partnerships across global pharma; comparable in scale, enterprise sales motion, and platform-as-engine approach to molecular design.

Broad incumbents

  • Schrödinger: Computational chemistry and predictive modeling platform serving pharma R&D; broader portfolio of tools and customers but overlaps significantly with Deep Genomics on AI-enabled molecular design and enterprise pharma go-to-market.
  • Ionis Pharmaceuticals: Established antisense oligonucleotide therapeutics leader with broad pipeline and partnerships; sets the bar for RNA-targeted genetic medicines and competes with Deep Genomics' oligonucleotide design approach at the modality level.

Emerging players

  • Wave Life Sciences: Clinical-stage RNA therapeutics company with proprietary chemistry platform; simultaneously a strategic partner of Deep Genomics and a modality peer — both design nucleic-acid therapeutics for genetic diseases.
  • Stoke Therapeutics: RNA-based medicine company using antisense oligonucleotides for genetic diseases; targets similar rare-disease indications as Deep Genomics and competes for partnership and licensing opportunities.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Deep Genomics social profiles

Digital presence

Deep Genomics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Deep Genomics leadership team

Management profile

Number of profiles

Profiles17 records

Deep Genomics funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Deep Genomics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Deep Genomics

What does Deep Genomics do?

Deep Genomics operates an AI-driven genetic medicines platform (the BioFM Platform) that uses proprietary biological foundation models—including BigRNA, REPRESS, and DeepADAR—to predict RNA biology mechanisms and design oligonucleotide-based therapeutic candidates for rare genetic diseases. The company partners with pharmaceutical companies like BioMarin and Wave Life Sciences to advance these candidates through clinical development and commercialization in exchange for upfront payments, milestones, and royalties.

Is Deep Genomics a public or private company?

Deep Genomics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Deep Genomics founded?

Deep Genomics was founded in 2015. It employs 101 to 250 people.

Where is Deep Genomics based?

Deep Genomics is headquartered in Toronto, Canada, in the North America region.

How does Deep Genomics make money?

Two revenue lines are on record. Partnership and Collaboration Revenue is the primary driver. The others are pipeline Development and Licensing.

Who are Deep Genomics's main competitors?

Direct peers on record are Recursion Pharmaceuticals, Insitro, Generate:Biomedicines, Isomorphic Labs, Exscientia and XtalPi. Broad incumbents are Schrödinger and Ionis Pharmaceuticals. Emerging players are Wave Life Sciences and Stoke Therapeutics.

Does Deep Genomics have an API?

No public API is recorded for Deep Genomics.

What industry is Deep Genomics in?

Deep Genomics's product category is AI-driven drug discovery platform. Its primary akta.pro industry code is HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics), with a secondary code of HLAAADAE, RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Medical BuyerCanada emerges as innovative center for AI, ML in healthcareCanada is emerging as a leader in AI and machine learning for healthcare diagnostics, with applications in radiology, genomics, and clinical decision support. Companies like Deep Genomics and platforms such as Iris are developing tools to improve accuracy and reduce waiting times. The article notes challenges including regulatory oversight and data governance.Digital JournalCanada is pushing ahead with machine learning to improve medical diagnosticsCanada is advancing machine learning for medical diagnostics, with initiatives like Iris and Deep Genomics. The technology aims to improve accuracy, reduce waiting times, and enable earlier disease detection, particularly in radiology and genomics. Challenges include regulatory oversight and data governance.citybizDeep Genomics Appoints Thong Q. Le as Chair of Board of DirectorsDeep Genomics has appointed Thong Q. Le as chair of its Board of Directors, succeeding Chip Baird who served in the role for three years and will remain as a non-executive director. Le, who brings over two decades of life sciences investment experience and currently serves as investment director at the Gates Foundation's Strategic Investment Fund, will guide the company through its next stage of growth as it advances its AI-driven drug discovery pipeline toward clinical development. The appointment strengthens Deep Genomics' governance and strategic leadership at a key juncture in the company's development of genomic medicines through its Biological Foundation Model platform.Financial PostDeep Genomics Appoints Thong Q. Le as Chair of the Board of DirectorsDeep Genomics announced the appointment of Thong Q. Le as Chair of its Board of Directors, succeeding Chip Baird who had served in the role for three years. Le brings over 20 years of experience investing in the life sciences sector and currently serves as investment director and managing partner of the Gates Foundation's Strategic Investment Fund, as well as chairman of Accelerator Life Science Partners. Baird will remain with the company as a non-executive director and Chair of the Audit Committee.FinancialContent Business PageDeep Genomics Appoints Thong Q. Le as Chair of the Board of DirectorsDeep Genomics announced the appointment of Thong Q. Le as Chair of its Board of Directors, effective immediately. Le, who joined the board in 2025, brings over 20 years of experience investing in the life sciences sector and currently serves as investment director of the Gates Foundation's Strategic Investment Fund and chairman of Accelerator Life Science Partners. He succeeds Chip Baird, who will remain as a non-executive director and Chair of the Audit Committee.Business Wire BlogDeep Genomics Appoints Thong Q. Le as Chair of the Board of DirectorsDeep Genomics appointed Thong Q. Le as chair of its board of directors, succeeding Chip Baird. Le brings over 20 years of life sciences investment experience and will guide the company's growth toward clinical development and strategic collaborations.GlobeNewswireAI in Biotechnology Market to Reach $11.4 Billion by 2030The global AI in biotechnology market is projected to grow from $4.6 billion in 2025 to $11.4 billion by 2030, representing a compound annual growth rate of 20%, up from a $3.8 billion valuation in 2024. Key growth drivers include the approaching patent cliff for blockbuster biologic drugs such as Keytruda and Opdivo by 2030, increasing demand for personalized medicine, and the need to reduce lengthy drug development timelines and high R&D costs. Leading companies driving this transformation include Nvidia, Tempus AI Inc., Recursion Pharmaceuticals, Schrödinger Inc., and Sophia Genetics, with venture capital funding flowing into AI-focused startups such as Insilico Medicine and Deep Genomics for de novo molecule generation and genomic insights.Deep GenomicsDeep GenomicsDeep Genomics describes its proprietary AI platform, BigRNA, as the world’s first RNA foundation model designed for drug discovery and therapeutics. The platform utilizes large machine learning models to predict RNA expression at sub-gene resolution, aiming to identify new biological mechanisms and therapeutic candidates more effectively than traditional approaches.PharmiWeb.comThong Q. Le and Paul Sekhri Join Board of Directors at Deep GenomicsDeep Genomics announced the appointment of Thong Q. Le and Paul Sekhri to its Board of Directors, effective immediately. Thong Q. Le brings over two decades of life sciences investment experience, currently serving as investment director and managing partner of the Strategic Investment Fund for the Gates Foundation and chairman of Accelerator Life Science Partners. Paul Sekhri, with over 35 years of experience, currently serves as Chair, President and CEO of vTv Therapeutics, Chair of Resolution Therapeutics, and Executive Chair of Violet Therapeutics, having previously held senior leadership roles at Sanofi, Teva Pharmaceuticals, Novartis, and other companies.